Isomorphic Labs is preparing to test AI-designed drugs in humans, marking a new phase in drug development with artificial ...

Google's DeepMind spinoff Isomorphic Labs expects clinical trial of drugs it designed using AI to start this year, Bloomberg News reported, citing the company's CEO Demis Hassabis.

An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end.

Isomorphic Labs, the AI-powered drug company spun out of Google’s DeepMind, just announced that it’s “getting ready” to begin human clinical trials of drugs designed by AI.

Isomorphic was spun out of Google’s AI research arm Google DeepMind in 2021, but remains a wholly owned subsidiary of its parent company, Alphabet.

DeepMind is looking beyond current frontier AI to artificial general intelligence (AGI), human-level smarts, which could revolutionize healthcare and other industries or trigger technological chaos.

After years of development, the company says it’s now gearing up for human clinical trials of cancer drugs, treatments designed entirely by artificial intelligence. The company was spun out of Google ...

Google DeepMind spinoff Isomorphic Labs expects testing on its first AI-designed drugs to begin this year, as tech startups race to turn algorithmic magic into actual treatments. “We’ll ...

Google's DeepMind spinoff Isomorphic Labs expects clinical trial of drugs it designed using AI to start this year.